Evolent Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2023 Annual Meeting of Stockholders held by Evolent Health, Inc. on June 8, 2023. The filing details the voting outcomes for four specific proposals presented to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on four proposals with the following outcomes:
- Proposal 1 (Election of Directors): All nine nominees were elected. While most received overwhelming support, Craig Barbarosh and Diane Holder received approximately 8.1 million and 7.8 million "Against" votes, respectively, compared to significantly fewer against votes for other nominees.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Proposal 3 (Executive Compensation): Stockholders approved the 2022 compensation of named executive officers on an advisory basis.
- Proposal 4 (Incentive Plan Amendment): Stockholders approved the amendment to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific reasons for the higher "Against" vote count for directors Craig Barbarosh and Diane Holder compared to other board members.
- Confirm the details of the amendment to the 2015 Omnibus Incentive Compensation Plan approved in Proposal 4.
- Review the definitive proxy statement (Schedule 14A) filed on April 28, 2023, for full context on the proposals and director biographies.